| Characteristic . | Co-Ad N = 523 . | Control N = 522 . |
|---|---|---|
| Mean age (SD), y | 72.1 (5.4) | 72.2 (5.2) |
| Age group, n (%) | ||
| 65–69 y | 200 (38.2) | 198 (37.9) |
| 70–79 y | 269 (51.4) | 271 (51.9) |
| ≥80 y | 54 (10.3) | 53 (10.2) |
| Sex, n (%) | ||
| Female | 268 (51.2) | 247 (47.3) |
| Male | 255 (48.8) | 275 (52.7) |
| Race, n (%) | ||
| Asian | 0 (0.0) | 1 (0.2) |
| Black | 0 (0.0) | 1 (0.2) |
| White | 522 (99.8) | 516 (98.9) |
| Other | 1 (0.2) | 3 (0.6) |
| Unknown | 0 (0.0) | 1 (0.2) |
| Country, n (%) | ||
| Belgium | 60 (11.5) | 61 (11.7) |
| Finland | 55 (10.5) | 55 (10.5) |
| France | 111 (21.2) | 112 (21.5) |
| Spain | 224 (42.8) | 220 (42.1) |
| United Kingdom | 73 (14.0) | 74 (14.2) |
| Any pre-existing conditiona | 488 (93.3) | 496 (95.0) |
| Characteristic . | Co-Ad N = 523 . | Control N = 522 . |
|---|---|---|
| Mean age (SD), y | 72.1 (5.4) | 72.2 (5.2) |
| Age group, n (%) | ||
| 65–69 y | 200 (38.2) | 198 (37.9) |
| 70–79 y | 269 (51.4) | 271 (51.9) |
| ≥80 y | 54 (10.3) | 53 (10.2) |
| Sex, n (%) | ||
| Female | 268 (51.2) | 247 (47.3) |
| Male | 255 (48.8) | 275 (52.7) |
| Race, n (%) | ||
| Asian | 0 (0.0) | 1 (0.2) |
| Black | 0 (0.0) | 1 (0.2) |
| White | 522 (99.8) | 516 (98.9) |
| Other | 1 (0.2) | 3 (0.6) |
| Unknown | 0 (0.0) | 1 (0.2) |
| Country, n (%) | ||
| Belgium | 60 (11.5) | 61 (11.7) |
| Finland | 55 (10.5) | 55 (10.5) |
| France | 111 (21.2) | 112 (21.5) |
| Spain | 224 (42.8) | 220 (42.1) |
| United Kingdom | 73 (14.0) | 74 (14.2) |
| Any pre-existing conditiona | 488 (93.3) | 496 (95.0) |
Abbreviations: Co-Ad, group of participants who received RSVPreF3 OA and FLU-aQIV concomitantly on day 1; Control, group of participants who received FLU-aQIV on day 1 and RSVPreF3 OA on day 31; FLU-aQIV, adjuvanted inactivated seasonal quadrivalent influenza vaccine; N, number of participants in the exposed set; n (%), number (percentage) of participants in the indicated category. RSVPreF3 OA, respiratory syncytial virus (RSV) prefusion F protein-based vaccine; SD, standard deviation.
aAny pre-existing medical condition based on the participant's medical history obtained by interviewing the participant and/or reviewing the participant's medical records. The most common conditions were hypertension (Co-Ad: 45.3%, Control: 44.6%) and hypercholesterolemia (Co-Ad: 22.2%; Control: 21.5%). Additional data related to pre-existing medical conditions are included in Supplementary Table 2.
| Characteristic . | Co-Ad N = 523 . | Control N = 522 . |
|---|---|---|
| Mean age (SD), y | 72.1 (5.4) | 72.2 (5.2) |
| Age group, n (%) | ||
| 65–69 y | 200 (38.2) | 198 (37.9) |
| 70–79 y | 269 (51.4) | 271 (51.9) |
| ≥80 y | 54 (10.3) | 53 (10.2) |
| Sex, n (%) | ||
| Female | 268 (51.2) | 247 (47.3) |
| Male | 255 (48.8) | 275 (52.7) |
| Race, n (%) | ||
| Asian | 0 (0.0) | 1 (0.2) |
| Black | 0 (0.0) | 1 (0.2) |
| White | 522 (99.8) | 516 (98.9) |
| Other | 1 (0.2) | 3 (0.6) |
| Unknown | 0 (0.0) | 1 (0.2) |
| Country, n (%) | ||
| Belgium | 60 (11.5) | 61 (11.7) |
| Finland | 55 (10.5) | 55 (10.5) |
| France | 111 (21.2) | 112 (21.5) |
| Spain | 224 (42.8) | 220 (42.1) |
| United Kingdom | 73 (14.0) | 74 (14.2) |
| Any pre-existing conditiona | 488 (93.3) | 496 (95.0) |
| Characteristic . | Co-Ad N = 523 . | Control N = 522 . |
|---|---|---|
| Mean age (SD), y | 72.1 (5.4) | 72.2 (5.2) |
| Age group, n (%) | ||
| 65–69 y | 200 (38.2) | 198 (37.9) |
| 70–79 y | 269 (51.4) | 271 (51.9) |
| ≥80 y | 54 (10.3) | 53 (10.2) |
| Sex, n (%) | ||
| Female | 268 (51.2) | 247 (47.3) |
| Male | 255 (48.8) | 275 (52.7) |
| Race, n (%) | ||
| Asian | 0 (0.0) | 1 (0.2) |
| Black | 0 (0.0) | 1 (0.2) |
| White | 522 (99.8) | 516 (98.9) |
| Other | 1 (0.2) | 3 (0.6) |
| Unknown | 0 (0.0) | 1 (0.2) |
| Country, n (%) | ||
| Belgium | 60 (11.5) | 61 (11.7) |
| Finland | 55 (10.5) | 55 (10.5) |
| France | 111 (21.2) | 112 (21.5) |
| Spain | 224 (42.8) | 220 (42.1) |
| United Kingdom | 73 (14.0) | 74 (14.2) |
| Any pre-existing conditiona | 488 (93.3) | 496 (95.0) |
Abbreviations: Co-Ad, group of participants who received RSVPreF3 OA and FLU-aQIV concomitantly on day 1; Control, group of participants who received FLU-aQIV on day 1 and RSVPreF3 OA on day 31; FLU-aQIV, adjuvanted inactivated seasonal quadrivalent influenza vaccine; N, number of participants in the exposed set; n (%), number (percentage) of participants in the indicated category. RSVPreF3 OA, respiratory syncytial virus (RSV) prefusion F protein-based vaccine; SD, standard deviation.
aAny pre-existing medical condition based on the participant's medical history obtained by interviewing the participant and/or reviewing the participant's medical records. The most common conditions were hypertension (Co-Ad: 45.3%, Control: 44.6%) and hypercholesterolemia (Co-Ad: 22.2%; Control: 21.5%). Additional data related to pre-existing medical conditions are included in Supplementary Table 2.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
